On our screens:Stocks with no debt
Is the price fair?
What INDV's price assumes
Indivior Pharmaceuticals, Inc. trades at 12.3× earnings against 24.3× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
12.3
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.3 · cheaper than the typical name in its group
- Price / sales
- 3.05
Price / sales · as of 2026-Q1
- EV / sales
- 3.29
EV / sales
Details›
- EV / EBIT2026-Q1
- 12.7
- EV / sales2026-Q1
- 3.29
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.3
- Market capitalisation
- $4.88B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #19 of 29 by Smart Score